Oncotarget

Research Papers:

Redox-dependent modulation of metformin contributes to enhanced sensitivity of esophageal squamous cell carcinoma to cisplatin

Pin Dong Li, Zhao Liu, Tian Tian Cheng, Wen Guang Luo, Jing Yao, Jing Chen, Zhen Wei Zou, Li Li Chen, Charlie Ma and Xiao Fang Dai _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:62057-62068. https://doi.org/10.18632/oncotarget.18907

Metrics: PDF 527 views  |   HTML 897 views  |   ?  


Abstract

Pin Dong Li1,*, Zhao Liu1,*, Tian Tian Cheng3, Wen Guang Luo4, Jing Yao1, Jing Chen1, Zhen Wei Zou1, Li Li Chen2, Charlie Ma2 and Xiao Fang Dai1

1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

2Department of Radiation Oncology, Fox Chase Cancer Center, American Oncologic Hospital, Philadelphia, PA 19111, USA

3Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 510095, China

4Department of Radiation Oncology, Anhui Provincial Hospital, Hefei 230001, China

*These authors have contributed equally to this work

Correspondence to:

Xiao Fang Dai, email: daixf2016@163.com

Keywords: esophageal squamous cell carcinoma, metformin, cisplatin, chemoresistance, redox

Received: September 24, 2016     Accepted: May 21, 2017     Published: July 01, 2017

ABSTRACT

Glutathione is the major intracellular anti-oxidant against reactive oxygen species and serves as a detoxification essential. The anti-diabetic drug metformin has been showed to exert anti-tumor activity via modulation of redox homeostasis. In this study, we provided evidence that metformin inhibits proliferation and induces apoptosis of esophageal squamous cancer cells. Importantly, we found that metformin acts as pro-oxidant via depletion of intracellular glutathione. Co-treatment with metformin reversed the elevated intracellular glutathione induced by cisplatin and therefore enhanced the sensitivity to cisplatin in vitro and in vivo. Taken together, our data indicate that combination of metformin with cisplatin may represent a novel therapeutic strategy for esophageal squamous cell carcinoma treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18907